Preclinical vs Phase 2 — Oncology Deal Valuation Comparison

Preclinical Median Upfront

$32M

Total: $504M

Phase 2 Median Upfront

$258M

Total: $1.6B

Stage Premium

225%

Phase 2 premium over Preclinical

Preclinical Royalties

5.4%-10.7%

vs Phase 2: 11.8%-19.3%

Model Your Deal

Market Analysis

The Preclinical to Phase 2 transition in oncology represents a significant value inflection point. Phase 2 deals carry a median total deal value of $1.6B compared to $504M at Preclinical, a 225% premium reflecting clinical de-risking. Upfront payments increase from $32M to $258M.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the deal value premium from Preclinical to Phase 2 in oncology?

Phase 2 oncology deals command a 225% premium over Preclinical in total deal value ($1.6B vs $504M). Upfronts increase from $32M to $258M, reflecting the de-risking value of clinical progression.

How do deal structures differ between Preclinical and Phase 2 in oncology?

Preclinical deals are more milestone-weighted (94% milestones), reflecting higher clinical risk. Phase 2 deals shift toward higher upfront allocations (16% upfront) as clinical de-risking reduces the need for contingent milestone structures.

When is the optimal time to license a oncology asset?

The optimal licensing window depends on strategic priorities. Preclinical assets offer lower entry cost for licensees, while Phase 2 assets provide more certainty. The 225% premium from Preclinical to Phase 2 reflects the value created by clinical data, making the transition point critical for deal timing.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Preclinical vs Phase 2 — Oncology Deal Valuation Comparison

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Preclinical Oncology Deals

Phase 2 Oncology Deals

Phase 2 Deal Benchmarks

Ready to Calculate Your Deal Terms?